Clinical Trial: Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
Study Status: Completed
Recruit Status: RECRUITING
Condition: High Grade Astrocytic Tumor
Study Type: INTERVENTIONAL
Official Title: Efficacy and Safety Study of Neoadjuvant Efineptakin Alfa (NT-I7) and Pembrolizumab in Recurrent Glioblastoma
Brief Summary:
This phase II trial tests the safety and side effects of efineptakin alfa and pembrolizumab in treating patients with glioblastoma that has come back (recurrent).Efineptakin alfa is an immunotherapy drug that works by helping the immune system fight tumor cells.Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.Giving efineptakin alfa and pembrolizumab may kill more tumor…
Read more